Renschler Markus F.'s most recent trade in Cyteir Therapeutics Inc was a trade of 12,607 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Feb. 29, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 29 Feb 2024 | 12,607 | 1,094,820 | - | 1.7 | 21,306 | Common Stock |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 12,607 | 226,952 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 6,304 | 220,648 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 29 Feb 2024 | 6,304 | 1,103,661 | - | 1.7 | 10,654 | Common Stock |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 2,537 | 0 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 29 Feb 2024 | 2,537 | 1,097,357 | - | 1.2 | 3,044 | Common Stock |
| Cyteir Therapeutics Inc | F. Renschler Markus | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 6,304 | 239,559 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Markus Renschler F. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 11 Dec 2023 | 6,304 | 1,079,677 | - | 1.7 | 10,654 | Common Stock |
| Cyteir Therapeutics Inc | Markus Renschler F. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 2,536 | 2,537 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Renschler Markus F. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 11 Dec 2023 | 2,536 | 1,082,213 | - | 1.2 | 3,043 | Common Stock |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 302,600 | 302,600 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.49 per share. | 03 Feb 2023 | 5,000 | 983,736 | - | 1.5 | 7,450 | Common Stock |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2022 | 106,345 | 0 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 21 Dec 2022 | 106,345 | 948,299 | - | 1.0 | 109,535 | Common Stock |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2022 | 30,437 | 32,973 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 21 Dec 2022 | 30,437 | 978,736 | - | 1.2 | 36,524 | Common Stock |
| Cyteir Therapeutics Inc | Markus F. Renschler | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 106,200 | 106,200 | - | - | Stock Option (Right to Buy) |